The Drugs Controller General of India has approved the emergency use of Covid-19 vaccine Sputnik V, the Russian Direct Investment Fund said on Tuesday.
The Russian vaccine is being developed in India in partnership with Dr Reddy’s Laboratories in Hyderabad. Sputnik V will be the third vaccine to be used in India after Serum Institute of India’s Covaxin and Bharat Biotech’s Covishield.
“The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces that Drug Controller General of India (DCGI) has approved the use of the Russian Sputnik V vaccine against coronavirus in the country,” the RDIF said. “India has become the 60th country to approve Sputnik V.”
Sputnik V had shown a 91.6% efficacy in late-stage trials, according to results published earlier this year. The vaccine is administered in two doses separated by 21 days, and requires a minus 18-20 degree Celsius cold chain to remain stable.
“The vaccine has been registered in India under the emergency use authorisation procedure based on results of clinical trials in Russia as well as positive data of additional Phase III local clinical trials in India conducted in partnership with Dr Reddy’s Laboratories,” the Russian Direct Investment Fund’s statement read.